Which manufacturer is Bedaquiline Fumarate Tablets?

Bedaquiline (Bedaquiline) is a new anti- tuberculosis drug, specially used to treat patients with multi-drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Its mechanism of action is unique. It blocks bacterial energy metabolism by inhibiting Mycobacterium tuberculosis ATP synthase, thereby effectively inhibiting the reproduction of drug-resistant strains. The drug was first developed by Janssen Therapeutics (part of the Johnson & Johnson Group) and introduced to the global market under the trade name SIRTURO®. Janssen is not only responsible for the clinical development and registration application of drugs, but also manages drug production and quality control to ensure stable supply and compliance with international quality standards.

As an original research company, Janssen distributes drugs through local registration and partner systems around the world, and also provides clinical use guidelines and drug safety monitoring solutions. In the domestic market, Janssen is responsible for drug registration and marketing authorization management, and its production of bedaquiline fumarate tablets provides patients with a reliable source of original drugs. In recent years, as multidrug-resistant tuberculosis has attracted increasing attention worldwide, pharmaceutical companies in some countries and regions have also participated in the production of raw materials and the development of generic drugs to meet the demand for drug accessibility. However, the research and development, clinical data and registration system of original drugs are still controlled by Janssen.

The launch of bedaquiline fumarate marks a major breakthrough in the development of anti-tuberculosis drugs. It is the first oral anti-tuberculosis drug with a new mechanism for multi-drug-resistant tuberculosis in recent decades. Janssen, the manufacturer of the original drug, not only has strict requirements on drug production and quality management, but also provides clinical and policy support for global multi-drug-resistant tuberculosis treatment. Although generic drugs have been launched in overseas markets, original drugs still have core advantages in terms of efficacy stability, clinical evidence base, and policy inclusion.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline